We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

HospiMedica

Download Mobile App
Recent News Medica 2024 AI Critical Care Surgical Techniques Patient Care Health IT Point of Care Business Focus

Dilon Acquires Navigator Gamma Probe Company

By HospiMedica International staff writers
Posted on 13 Jan 2014
Dilon Technologies, Inc. (Newport News, VA, USA) has acquired the assets of the Navigator gamma probe business from RMD Instruments Corp. (Watertown, MA, USA), a subsidiary of Dynasil Corporation of America.

RMD Instruments manufactures and sells a range of intraoperative surgical probes that are distributed both in the United States and worldwide. The acquired products are used in surgery for procedures such as pulmonary wedge resection and sentinel lymph node biopsy. The company recently introduced its Navigator 2.0 wireless probe, which has been very well received by the market place.

“In addition to our market leadership in the small field-of-view molecular breast imaging market, this acquisition is consistent with our objective of expanding our product offering in both the diagnostic and surgical segments of the market and comes on the heels of our recent agreement with Digirad [Suwanee, GA, USA],” commented Robert G. Moussa, Dilon’s CEO.

“We are pleased to have found a wonderful home for our Navigator Probe technology, one of the most widely used gamma probes for cancer surgery in the marketplace. Dilon Technologies is well situated to expand the gamma probe market and we look forward to working with them over the coming months to transition the product from our manufacturing facility to Dilon,” commented Peter Sulick, Dynasil’s chairman and interim CEO.

Dynasil, for the time being, will continue to manufacture and distribute the products, maintaining continuity in supply and regulatory compliance.

Dilon Technologies’ keystone product, the Dilon molecular imaging system (MBI), is a high-resolution, small field-of-view digital gamma camera, optimized for MBI/breast-specific gamma imaging (BSGI). MBI utilizes radiotracer uptake to detect the increased metabolic activity of breast lesions and therefore, is not affected by breast density. Both the Dilon 6800 and Acella systems provide high photon sensitivity; and Dilon’s GammaLoc system is the only localization device on the market to enable molecular-guided breast biopsy.

Digirad is one of the largest US providers of in-office nuclear cardiology imaging and ultrasound services to physician practices, hospitals and imaging centers, and also sells medical diagnostic imaging systems for nuclear cardiology and general nuclear medicine applications.

Related Links:

Dilon Technologies
RMD Instruments
Digirad



Gold Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
New
Gold Member
X-Ray QA Meter
T3 AD Pro
New
Electric Cast Saw
CC4 System
New
Documentation System For Blood Banks
HettInfo II

Latest Business News

MEDICA 2024 to Highlight Hot Topics of MedTech Industry

Start-Ups To Once Again Play Starring Role at MEDICA 2024

Boston Scientific to Acquire AFib Ablation Company Cortex